

溫州康寧醫院股份有限公司

Wenzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China)

Stock code: 2120

Interim Results Announcement For the Six Months Ended June 30, 2017

1 INTRODUCTION

1.1 B. 30, 2016.

1.2 (Financial Report) A B 30, 2016 A B

2 PRINCIPAL FINANCIAL DATA AND INDICATORS

	For the six months ended June 30,	
	2017 <i>RMB'000</i> <i>(Unaudited)</i>	2016 <i>RMB'000</i> <i>(Audited)</i>
Revenue	283,136	189,680
Cost of sales	42,319	36,818
Gross profit	(12,014)	(10,531)
Operating expenses	30,305	26,287
Operating income	31,710	28,208
Non-operating income	(1,405)	(1,921)
As of June 30,		As of June 30,
2017		2016
<i>(RMB'000)</i>		<i>(RMB'000)</i>
<i>(Unaudited)</i>		<i>(Audited)</i>

3 BUSINESS REVIEW AND OUTLOOK


2017, V_P

2017, 2017, 2016, 8, 30, 2017, 10 (31, 2016: 8) 3,050 (31, 2016: 2,577).

[illegible][illegible]

4 MANAGEMENT DISCUSSION AND ANALYSIS

4.1 Financial Review



4.1.1 Revenue and Cost of Revenue

The following table shows the revenue and cost of revenue for the periods indicated below. The revenue is shown in millions of dollars and the cost of revenue is shown in millions of dollars.

Period	Revenue	Cost of Revenue
2016	()	()
2017	()	()

	For the six months ended June 30,	
	2017	2016
Revenue from sales of pharmaceutical products	3,050	2,300
Revenue from sales of medical equipment	552,050	418,600
Revenue from sales of medical consumables (%)	85.9%	88.6%
Revenue from sales of medical services	474,163	370,702
Revenue from sales of medical consumables (RMB'000)	158,561	121,743
Revenue from sales of medical consumables (RMB)	334	329
Revenue from sales of medical consumables (RMB'000)	28,427	21,980
Revenue from sales of medical consumables (RMB)	60	59
Total inpatient revenue (RMB'000)	186,988	143,723
Total average inpatient spending per bed-day (RMB)	394	388
Revenue from sales of medical consumables	75,872	68,875
Revenue from sales of medical consumables (RMB'000)	7,665	7,673
Revenue from sales of medical consumables (RMB)	101	112
Revenue from sales of medical consumables (RMB'000)	31,876	27,583
Revenue from sales of medical consumables (RMB)	420	400
Total outpatient revenue (RMB'000)	39,541	35,256

	For the six months ended June 30,	
	2017	2016
Total average outpatient spending per visit (RMB)	<u>524</u>	<u>512</u>
Total treatment and general healthcare services revenue (RMB'000)	<u>166,226</u>	<u>129,416</u>
Total pharmaceutical sales revenue (RMB'000)	<u>60,303</u>	<u>49,563</u>

2016, 30.1% (2016: 27.9%)

2016, 1.6% (2016: 82.5%)

2016: 80.3%).

2016, 12.2% (2016: 10.2%)

2.3%

2016: 19.7%),

0.339 (2016: 0.284)

0.284 (2016: 0.284)

2016年6月30日，本公司拥有的医院资产账面价值为人民币151,633千元，较2015年12月31日的人民币144,834千元增加4.7%。

	For the six months ended June 30,	
	2017	2016
	(RMB'000)	(RMB'000)
	(Unaudited)	(Unaudited)
折旧及摊销	58,173	48,086
减值损失	50,903	39,834
公允价值变动	9,857	4,785
处置收益	13,642	7,103
汇兑损益	8,120	6,544
其他	4,182	2,180
合计	6,756	6,094
Cost of revenue for owned hospitals	151,633	114,626

2016年6月30日，本公司拥有的医院资产账面价值为人民币151,633千元，较2015年12月31日的人民币144,834千元增加4.7%。

2016年6月30日，本公司拥有的医院资产账面价值为人民币151,633千元，较2015年12月31日的人民币144,834千元增加4.7%。

2016年6月30日，本公司拥有的医院资产账面价值为人民币151,633千元，较2015年12月31日的人民币144,834千元增加4.7%。

2016年6月30日，本公司拥有的医院资产账面价值为人民币151,633千元，较2015年12月31日的人民币144,834千元增加4.7%。

2016年6月30日，本公司拥有的医院资产账面价值为人民币151,633千元，较2015年12月31日的人民币144,834千元增加4.7%。

2016年6月30日，本公司拥有的医院资产账面价值为人民币151,633千元，较2015年12月31日的人民币144,834千元增加4.7%。

2016年6月30日，本公司拥有的医院资产账面价值为人民币151,633千元，较2015年12月31日的人民币144,834千元增加4.7%。

2016年6月30日，本公司拥有的医院资产账面价值为人民币151,633千元，较2015年12月31日的人民币144,834千元增加4.7%。

14. 2017年6月30日，本公司应收账款账面余额为人民币11,579,000.00元，坏账准备为人民币5,252,000.00元，计提比例为45.36%。2016年6月30日，本公司应收账款账面余额为人民币8,838,000.00元，坏账准备为人民币4,319,000.00元，计提比例为48.98%。

	For the six months ended June 30,	
	2017	2016
	(RMB'000)	(RMB'000)
	(Unaudited)	(Unaudited)
应收账款	11,579	8,838
坏账准备	5,252	4,319
计提比例	6,327	4,519

15. 截至2017年6月30日，本公司应收账款账龄分析如下：

账龄	2017年6月30日	2016年6月30日
1年以内	11,579	8,838
1-2年	5,252	4,319
2-3年	6,327	4,519

16. 截至2017年6月30日，本公司应收账款前五名客户余额合计为人民币3,100,000.00元，占应收账款余额的26.77%。2016年6月30日，本公司应收账款前五名客户余额合计为人民币2,160,000.00元，占应收账款余额的24.45%。

17. 截至2017年6月30日，本公司应收账款中无应收关联方款项。2016年6月30日，本公司应收账款中无应收关联方款项。

18. 截至2017年6月30日，本公司应收账款中无应收政府补助。2016年6月30日，本公司应收账款中无应收政府补助。

19. 截至2017年6月30日，本公司应收账款中无应收出口退税。2016年6月30日，本公司应收账款中无应收出口退税。

20. 截至2017年6月30日，本公司应收账款中无应收利息。2016年6月30日，本公司应收账款中无应收利息。

21. 截至2017年6月30日，本公司应收账款中无应收股利。2016年6月30日，本公司应收账款中无应收股利。

22. 截至2017年6月30日，本公司应收账款中无应收其他款项。2016年6月30日，本公司应收账款中无应收其他款项。

23. 截至2017年6月30日，本公司应收账款中无应收其他款项。2016年6月30日，本公司应收账款中无应收其他款项。

24. 截至2017年6月30日，本公司应收账款中无应收其他款项。2016年6月30日，本公司应收账款中无应收其他款项。

25. 截至2017年6月30日，本公司应收账款中无应收其他款项。2016年6月30日，本公司应收账款中无应收其他款项。

26. 截至2017年6月30日，本公司应收账款中无应收其他款项。2016年6月30日，本公司应收账款中无应收其他款项。


27. 截至2017年6月30日，本公司应收账款中无应收其他款项。2016年6月30日，本公司应收账款中无应收其他款项。

28. 截至2017年6月30日，本公司应收账款中无应收其他款项。2016年6月30日，本公司应收账款中无应收其他款项。

29. 截至2017年6月30日，本公司应收账款中无应收其他款项。2016年6月30日，本公司应收账款中无应收其他款项。

30. 截至2017年6月30日，本公司应收账款中无应收其他款项。2016年6月30日，本公司应收账款中无应收其他款项。

4.1.2 Gross Profit and Gross Profit Margin



	For the six months ended June 30,	
	2017 (Unaudited)	2016 (Unaudited)
Gross profit	38.6%	43.0%
Gross profit margin	17.9%	17.6%
Gross profit margin	54.6%	51.1%
Gross profit margin	23.9%	66.0%
Consolidated gross profit margin	32.5%	37.0%

32.5% (2016: 37.0%),

34.1%, 2.9

2016,

4.1.3 Tax and Surcharge

B3.9 (2016: B34.1),

W

4.1.4 Selling Expenses

B0.4 (2016: B1.0),

56.3%

0.2% (2016: 0.5%),

2016.

4.1.5 Administrative Expenses

Administrative expenses are \$240,533.00, () 0.53300, () 0.17.

4.1.6 Finance (Expenses)/Income – Net

For the six months ended June 30, 2017, the Company incurred net finance expenses of RMB10,437,000 (2016: RMB9,786,000 income). The net finance expenses were mainly attributable to the increase in the interest expense on bank borrowings and the decrease in the interest income on bank deposits.

	For the six months ended June 30,	
	2017	2016
	(RMB'000)	(RMB'000)
	(Unaudited)	(Unaudited)
Interest expense	1,907	3,102
Interest income	(7,730)	9,592
Bank charges	(1,691)	-
Net finance expenses	(2,725)	(2,777)
Finance income	(198)	(131)
Finance (expenses)/income – Net	(10,437)	9,786

2016, () B10.4 B20.2 B7.7 B17.3 B1.7

4.1.7 Investment Income/(Loss)

$$I(\dots) \rightarrow I(\dots) \xrightarrow{V_P^0} I(\dots) \xrightarrow{V_P^0} I(\dots)$$

**For the six months
ended June 30,**

	2017 (RMB'000) (Unaudited)	2016 (RMB'000) (Audited)
Depreciation and amortization expense	(2,852)	(2,200)
Impairment loss on property, plant and equipment	5,243	-
Impairment loss on financial assets	2,391	(2,200)

Figure 1 consists of four pie charts arranged in a 2x2 grid. The top row shows responses for questions B2.1 and B2.2, and the bottom row shows responses for B5.1 and B5.2. Each chart compares responses from 30, 2016 (left) and 30, 2017 (right). The legend indicates that 'H' (Harmful) is represented by dark grey and 'B' (Beneficial) is represented by light grey. The percentages for 'Harmful' responses are: B2.1 (30, 2016: 49.0%, 30, 2017: 32.7%), B2.2 (30, 2016: 49.0%, 30, 2017: 32.7%), B5.1 (30, 2016: 16.3%, 30, 2017: 32.7%), and B5.2 (30, 2016: 16.3%, 30, 2017: 32.7%).


4.1.8 Assets Impairment Losses

(30, 2016: B1.2), B2.8
137.4% 2016
1.2% (30, 2016:
0.6%),
31, 2016, B10.4
5.4% A 30, 2017 B8.1 5.1%
2016,

4.1.9 Non-Operating Income (Expenses) and Other Income

Non-operating income (expenses) and other income are reported in the income statement below operating income (expenses). These items are not part of the company's core operations and are therefore reported separately. They include items such as gains or losses from the sale of assets, interest income, and other non-recurring items.

4.1.11 Total Comprehensive Income



4.2 Financial Position

4.2.1 Inventory

A 30, 2017, B176.6 (31, 2016: B162.8), () B14.5 (31, 2016: B9.3); () B162.1 (31, 2016: B153.5), W B W z W

W B W z W A W z W z W

(2012) 3-289403

75%

(A) () 6,602.26

(A) () 30,557.34

J 30, 2017

4.2.2 Trade Receivables

A 30, 2017, B195.2 (31, 2016: B142.9), B189.4 32.5% 31, 2016, W W 2016.

125 ()
30, 2016: 120 ().

4.2.3 Other Receivables and Prepayments

A 30, 2017, B75.8 (31, 2016: B77.0).

4.2.4 Investment Properties

A 30, 2017, B72.2 (31, 2016: B72.2),
B (3 & 4)
W z H (3 & 4)
W z

W B W z H (3 & 4)

A W z H W z

W (2012) 3-290617 W
(2012) 3-290604 W (2012) 3-290602 W
(2012) 3-290616 W
(2012) 3-290595 W (2012) 3-290606 W
(2012) 3-290593 W
(2012) 3-290607

75%
(A) 3,722.29
()

12,854.06
(A) ()

W z H
W z H
50 (J 29, 2053),

4.2.5 Available-for-Sale Financial Assets

At December 31, 2017, the Company's available-for-sale financial assets consisted of \$50.0 million (2016: \$50.0 million),

4.2.6 Accounts Payable

At December 31, 2017, the Company's accounts payable consisted of \$80.5 million (2016: \$43.3 million),

4.2.7 Advanced from Customers

At December 31, 2017, the Company's advanced from customers consisted of \$390.3 million (2016: \$390.3 million),

4.3.1 Net Cash Generated from Operating Activities

A. 30, 2017,



Map A displays the western portion of the study area, including the coastline and the western end of the island. Five sampling locations are marked with black triangles and labeled: B30.3, B20.9, B58.3, B3.5, and B33.6. A north arrow is located in the upper right corner of the map.

4.3.2 Net Cash Used in Investing Activities

Figure 1 is a map of the study area in the northern Adriatic Sea. The map shows a coordinate grid with latitude from 43°N to 45°N and longitude from 12°E to 14°E. A scale bar indicates distances from 0 to 100 km. Bathymetric contours are marked at 100, 200, and 300 meters depth. Four sampling stations are identified: B134.7, B158.1, B37.9, and W. The map also shows the coastline of the Adriatic Sea and the location of the study area relative to the Italian coast.

4.3.3 Net Cash Generated from Financing Activities

4.3.4 Significant Investment, Acquisition and Disposal

30, 2017.

4.4 Indebtedness

4.4.1 Bank Borrowings

A. J. 30, 2017, M-B269.0 (M-B269.0), A. J. 31, 2016: M-B216.7 (M-B216.7), A. J. 32, 2015: M-B90.0 (M-B90.0), A. J. 33, 2014: M-B37.7 (M-B37.7).

4.4.2 Contingent Liabilities

A. J. 30, 2017, *Journal of the American Medical Association*, 318(16), pp. 1591-1592.

4.4.3 Asset Pledge

W $\boxtimes$ z, B, W $\boxtimes$ z, H, W $\boxtimes$ z, J, 30, 2017, B20.0, W $\boxtimes$ z, H, B, W $\boxtimes$ z, B, J, 30, 2017, B40.0.

4.4.4 Contractual Obligations

А. 30, 2017, № 4. В. 332.0

4.4.5 Financial Instruments

1. 1940年12月1日，在“大公报”发表“关于汪精卫”一文，指出汪精卫在抗战中的动摇性，并预言其必将叛变。

4.4.6 Exposure to Fluctuation in Exchange Rates

[illegible][illegible]

4.4.7 Gearing Ratio

A. $\chi^2_{\text{red}} = 30$, 2017, $\chi^2_{\text{red}} = 31$, 2016 (2017: 39.2% (2016: 35.1%).)

4.4.8 Employees and Remuneration Policy

A. J. 30, 2017, 1,589 (1,589).
 31, 2016: 1,348 (1,348).
 B71.3 (1,589).
 2016: B55.7 (1,348). B97.1 (1,589).

5 PURCHASE, SALE AND REDEMPTION OF LISTED SECURITIES

the *Journal of the American Medical Association* (JAMA) and the *New England Journal of Medicine* (NEJM) are the most widely read journals in the field of medicine. The *JAMA* is published by the American Medical Association (AMA) and the *NEJM* is published by the Massachusetts Medical Society. Both journals are highly respected and are considered to be the gold standard in the field of medicine. The *JAMA* is a weekly journal and the *NEJM* is a weekly journal. Both journals are published in English and are available online. The *JAMA* is available at www.jama-association.org and the *NEJM* is available at www.nejm.org.

6 REVIEW OF INTERIM RESULTS

A J 30, 2017

[illegible]

B. J. 30, 2017 (_____) J. 30, 2016: ____).

7 COMPLIANCE WITH CG CODE

1. *Principles of Mathematics* (1903) by Giuseppe Peano. This work is a foundational text in the foundations of mathematics, introducing the concept of natural numbers and the principle of mathematical induction.

9.2 Consolidated Interim Financial Information

附註 A 附註 B

9.2.1 Interim Consolidated Statement of Comprehensive Income

		Six months ended 30 June,	
		2017	2016
		RMB	HK\$
		(Unaudited)	(Unaudited)
1.	Revenue	283,136,307	189,680,305
	Cost of sales	(191,153,046)	(119,578,600)
	Gross profit	(3,937,078)	(34,107)
	Other income	(445,240)	(1,017,758)
	Other expenses	(39,814,343)	(36,359,241)
	Share of profit of associates	(10,436,551)	9,785,791
	Administrative expenses	(2,823,150)	(1,188,953)
	Finance expenses	2,390,872	(2,199,509)
	Finance income	(2,852,505)	(2,199,509)
	Profit before income tax	2,692,900	—
	Income tax	—	—
2.	Operating profit	39,610,671	39,087,928
	Other income	5,377,451	184,815
	Other expenses	(2,668,911)	(2,454,270)
	Share of profit of associates	(95,691)	(84,100)
3.	Total profit	42,319,211	36,818,473
	Other income	(12,013,726)	(10,531,210)

		Six months ended 30 June,	
		2017	2016
		<i>RMB</i>	<i>US\$</i>
		<i>(Unaudited)</i>	<i>(Unaudited)</i>
4.	Net profit	30,305,485	26,287,263

9.2.2 Interim Consolidated Statement of Financial Position

ASSETS	30 June 2017 RMB (Unaudited)	31 December 2016 RMB (Audited)
Current assets		
Accounts receivable	360,431,821	496,614,542
Accounts payable	195,213,586	142,938,440
Prepaid expenses	56,099,625	54,672,733
Other receivables	19,717,584	22,283,987
Other current assets	176,567,409	162,827,694
Net current assets	12,688,704	12,688,704
Total current assets	820,718,729	892,026,100
Non-current assets		
Accounts receivable	50,000,000	50,000,000
Accounts payable	60,198,228	22,429,070
Prepaid expenses	72,191,872	72,191,872
Other receivables	188,059,052	97,666,540
Other non-current assets	257,092,404	198,066,153
Net non-current assets	153,162,424	125,865,371
Other non-current assets	8,533,389	8,533,389
Accounts payable	109,388,448	88,855,792
Prepaid expenses	20,707,981	20,300,383
Other non-current assets	17,333,178	27,447,253
Total non-current assets	936,666,976	711,355,823
TOTAL ASSETS	1,757,385,705	1,603,381,923

	30 June 2017	31 2016
LIABILITIES AND OWNERS' EQUITY		
Current liabilities		
Accounts payable	120,000,000	30,000,000
Accounts receivable	80,476,871	43,271,014
Accounts payable - related parties	60,655,362	71,147,900
Accounts payable - other parties	15,316,095	19,552,350
Accounts payable - other parties	27,168,560	41,195,655
Accounts payable - other parties	87,816,113	38,922,694
Accounts payable - other parties	18,260,000	
Accounts payable - other parties	17,480,304	54,180,304
Total current liabilities	427,173,305	298,269,917
Non-current liabilities		
Accounts payable	148,950,190	149,950,190
Accounts payable	89,463,200	86,738,600
Accounts payable	10,632,800	10,632,800
Accounts payable	13,444,342	16,420,433
Total non-current liabilities	262,490,532	263,742,023
Total liabilities	689,663,837	562,011,940
Owners' equity		
Accounts payable	73,040,000	73,040,000
Accounts payable	795,919,512	795,604,861
Accounts payable	18,548,942	18,548,942
Accounts payable	134,640,863	121,190,550
Total equity attributable to owners of the parent company	1,022,149,317	1,008,384,353
Accounts payable	45,572,551	32,985,630
Total owners' equity	1,067,721,868	1,041,369,983
TOTAL LIABILITIES AND OWNERS' EQUITY	1,757,385,705	1,603,381,923

9.2.3 Interim Consolidated Statements of Cash Flow

	For the six months ended 30 June,	
	2017	2016
	RMB	MB
	(Unaudited)	(Unaudited)
1. Cash flows from operating activities		
Operating activities		
Income from operations	218,044,330	185,216,096
Income from disposal of subsidiaries	16,104,834	13,577,071
Sub-total of cash inflows	234,149,164	198,793,167
Operating activities		
Operating expenses	(84,493,508)	(57,860,296)
Operating expenses	(74,861,390)	(60,575,485)
Operating expenses	133,608,262	(14,053,392)
Operating expenses	(37,714,356)	(28,319,590)
Sub-total of cash outflows	(230,667,516)	(160,808,763)
Net cash flows generated from operating activities	3,471,648	37,984,404
2. Cash flows used in investing activities		
Investing activities		
Investing activities	3,225,000	—
Investing activities	—	2,039,728
Investing activities	91,007,687	898,631
Sub-total of cash inflows	94,232,687	2,938,359
Investing activities		
Investing activities	(158,053,650)	(71,372,976)
Investing activities	(37,878,286)	(88,096,114)
Investing activities	(33,000,000)	(2,500,000)
Sub-total of cash outflows	(228,931,936)	(161,969,090)
Net cash flows used in investing activities	(134,699,249)	(159,030,731)

		For the six months ended 30 June,	
		2017	2016
		RMB	¥
		(Unaudited)	(Unaudited)
3.	Cash flows from financing activities		
	Proceeds from bank loans	14,100,000	2,400,000
	Proceeds from bank deposits		
	Proceeds from bank deposits	14,100,000	2,400,000
	Proceeds from bank deposits	90,000,000	50,000,000
	Proceeds from bank deposits	300,000	
	Sub-total of cash inflows	104,400,000	52,400,000
	Interest expense	(37,700,000)	(30,000,000)
	Interest expense	(2,133,206)	
	Interest expense	(2,758,166)	(338,363)
	Sub-total of cash outflows	(42,591,372)	(30,338,363)
	Net cash flows generated from financing activities	61,808,628	22,061,637
4.	Effect of changes in foreign exchange rate	(7,312,748)	2,896,587
5.	Net decrease in cash and cash equivalents	(76,731,721)	(96,088,103)
	At the beginning of the period	407,163,542	368,457,171
6.	Cash and cash equivalents at end of the period	330,431,821	272,369,068

9.2.4 Interim Consolidated Statement of Changes In Equity

	Equity attributable to owners of the parent company				Non-controlling interests	Total owners' equity
	Share capital	Capital surplus	Surplus reserve	Retained earnings		
Balance at 1 January 2017	73,040,000	795,604,861	18,548,942	121,190,550	32,985,630	1,041,369,983
Net income	—	—	—	31,710,313	(1,404,828)	30,305,485
Dividends paid to owners	—	—	—	—	14,100,000	14,100,000
Share-based payment expense	—	206,400	—	—	—	206,400
Share-based payment expense	—	108,251	—	—	(108,251)	—
Share-based payment expense	—	—	—	(18,260,000)	—	(18,260,000)
Balance at 30 June 2017	<u>73,040,000</u>	<u>795,919,512</u>	<u>18,548,942</u>	<u>134,640,863</u>	<u>45,572,551</u>	<u>1,067,721,868</u>

Equity attributable to owners of the parent company				Non-controlling interests	Total owners
Share capital	Capital surplus	Surplus reserve	Retained earnings		

**95. Notes to the Consolidated Interim Financial Information prepared in accordance
with the Accounting Standard for Business Enterprises of the PRC**

9.3.3 Revenue and cost of sales

Six months ended 30 June	
2017	2016
<i>RMB</i>	<i>RMB</i>
<i>(Unaudited)</i>	<i>(Unaudited)</i>
Revenue from main operations	187,817,343
Revenue from other operations	1,862,962
238,108,930	
Cost of sales from main operations	
Cost of sales from other operations	
45,027,377	
283,136,307	189,680,305
Revenue from main operations	118,945,305
Revenue from other operations	
156,885,868	
34,267,178	
191,153,046	118,945,305

Revenue and cost of sale from main operations

Six months ended	
30 June 2017	
<i>RMB</i>	<i>RMB</i>
<i>(Unaudited)</i>	<i>(Unaudited)</i>
Revenue from main operations	Cost of sales from main operations
60,303,304	49,515,173
166,226,213	102,118,496
11,579,413	5,252,199
238,108,930	156,885,868

	30 June 2017	30 June 2016
	RMB	RMB
	(Unaudited)	(Unaudited)
Operating income	187,817,343	118,945,305
Operating expenses	(49,563,165)	(40,834,453)
Operating profit	129,416,332	73,791,802
Other income	8,837,846	4,319,050
Profit before income tax	<u>187,817,343</u>	<u>118,945,305</u>

9.3.4 Earnings per share

	Six months ended 30 June,	
	2017	2016
	RMB	RMB
	(Unaudited)	(Unaudited)
Profit attributable to equity holders of the Company	31,710,313	28,208,189
Profit attributable to equity holders of the Company	<u>73,040,000</u>	<u>73,040,000</u>
Weighted average number of shares outstanding	<u>0.43</u>	<u>0.39</u>

() B

30 June 2017. A

9.3.5 Income tax expenses

	Six months ended 30 June, 2017 RMB (Unaudited)	2016 RMB (Unaudited)
Income tax expense	14,743,399	13,915,240
Income tax credit	(2,729,673)	(3,384,030)
	<u>12,013,726</u>	<u>10,531,210</u>

Income tax expense is calculated based on the accounting profit before income tax, adjusted for non-deductible expenses and non-taxable income, and multiplied by the applicable income tax rate.

	Six months ended 30 June, 2017 RMB (Unaudited)	2016 RMB (Unaudited)
Income tax expense	42,319,211	36,818,473
Income tax credit	10,579,803	9,204,618
	<u>31,739,408</u>	<u>27,613,855</u>

9.3.6 Dividends

24, 2017,	B.	B18,260,000
31, 2016		73,040,000
	31, 2016.	
	A	
30, 2017.		
24, 2016,	B.	B18,260,000
31, 2015.		
14, 2016	2015	14, 2016.

10 DEFINITIONS

A	2016	14, 2017
A	B.	
B	B (北京怡寧醫院有限公司),	A 17, 2015 32.67%
B.	B.	
	(蒼南康寧醫院有限公司),	15, 2012,
	(成都仁一醫院有限公司),	29, 2010
	都濟宏醫院有限公司)	28, 2015
	(重慶合川康寧醫院有限公司),	5, 2015 40%

— **H** —

院) (淳安黃鋒康恩醫

— W —

— H —

W. J. ... H. ... B. ... (... : 2120)

—

A 14

History

怡寧老年醫院有限公司),

— — — — —

1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 2679, 26

Abstract

(杭州宏澜信息科技有限公司), 20, 2015 35%

$$H_1, H_2, \dots, H_n =$$

司), 2016年12月25日, 杭州怡寧醫院有限公司,

$\frac{1}{2}H$ \$-\frac{1}{2}H\$ -
 $\frac{1}{2}H$

[illegible]

History

How to Access the A-Z List of Journals

W

2. *How do you feel about the way you are being treated?*

... (臨海康寧醫院有限公司),
2, 2015,

... (平陽康寧醫院有限公司),
2, 2015,

... (平陽縣長庚醫院有限責任公司).

...

... (浦江黃鋒精神專科醫院)

...

А, 19, 2016,

J. 30, 2017

9, 2002,

26, 2015

12, 2012, _____,

3, 2013, ...

B B

A , 21, 2017